NCT06856278Not yet recruitingPhase 1/2
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)
Source: ClinicalTrials.gov · Last updated 4 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 26 Feb 2025
- Start date
- 22 Feb 2025
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Zhejiang Provincial People's Hospital
- Diseases
- Thyroid cancer
- NCT number
- NCT06856278
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 30
- From 22 Feb 2025 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Immune system diseases;
- Diseases of the blood system;
- Mental system diseases;
- Interstitial pneumonia, lung disease, etc.;
- Failure to follow rules of this study.
Other
- Need to breastfeed the baby or have fertility needs；
Who the study is looking for
- Age 18-75 years (including boundary values), male or female.
- Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.
- Liver and kidney function is good, and can tolerate treatment.
- Be able to cooperate with the completion of treatment and follow-up work.
- No other systemic diseases, including other malignancies.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Provincial People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.